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The prerequisite to prevent childhood B-cell acute lymphoblastic leukemia (B-ALL) is to
decipher its etiology. The current model suggests that infection triggers B-ALL development
through induction of activation-induced cytidine deaminase (AID; also known as AICDA) in
precursor B-cells. This evidence has been largely acquired through the use of ex vivo func-
tional studies. However, whether this mechanism governs native non-transplant B-ALL
development is unknown. Here we show that, surprisingly, AID genetic deletion does not
affect B-ALL development in Pax5-haploinsufficient mice prone to B-ALL upon natural
infection exposure. We next test the effect of premature AID expression from earliest pro-B-
cell stages in B-cell transformation. The generation of AID off-target mutagenic activity in
precursor B-cells does not promote B-ALL. Likewise, known drivers of human B-ALL are not
preferentially targeted by AID. Overall these results suggest that infections promote B-ALL
through AID-independent mechanisms, providing evidence for a new model of childhood
B-ALL development.
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The most common cancer in childhood is B-cell precursoracute lymphoblastic leukemia (B-ALL)1,2. Although theoverall survival is excellent, therapeutic options can be
associated with severe toxic side effects, and 20% of children still
relapse3. Thus, prevention approaches are undoubtedly preferred
to any therapy advance. The prerequisite to build strategies for
preventing B-ALL is to discover its etiology4. Somatic lesions of
the B-cell transcription factor gene PAX5 are characteristic of
B-ALL5,6, and this key role of PAX5 in the genesis of B-ALL has
been even broaden by recent discoveries of inherited PAX5
mutations associated to a syndrome of susceptibility to B-ALL7,8.
The presence of the PAX5 genetic alteration seems to create a
hidden preleukemic clone that remains latent until it is later
triggered by environmental stimuli9. Chronic infections during
early childhood were previously implicated in the etiology of
childhood B-ALL10–12. We have recently showed that natural
exposure to infectious pathogen induced development of overt
B-ALL in mice mimicking human preleukemic lesions, like Pax5-
haploinsuffiency or ETV6-RUNX1 fusion gene4,13.
Activation-induced deaminase (AID) plays a central role in the
immune response by triggering somatic hypermutation (SHM)
and class-switch recombination in germinal center B cells14. In
addition, AID is required for germinal center-derived lympho-
magenesis15–19 and a recent mouse model of endemic Burkitt
lymphoma, which is caused by chronic infection, identified AID
triggered infection-driven B-cell lymphomagenesis20. AID is not
generally expressed in early bone marrow B-cell precursors21.
However, the current view in the field of B-cell leukemogenesis
states that AID expression is induced in preleukemic B-cell pre-
cursor cells in response to infection and promotes in this case
secondary genetic changes that may lead to subsequent leukemia
development. However, evidence supporting this model has been
largely acquired through the use of ex vivo functional studies
involving bone marrow transplantation22–25. Whether AID also
contributes to native (non-transplant) B-ALL development is to
date entirely unclear. Based on these observations, we examined
here whether AID is required for clonal evolution of pre-
malignant precursor B cells in the etiology of B-ALL by using
both loss-of-function and gain-of-function genetic approaches.
Overall, our results suggest that infectious stimuli can promote
malignant B-cell leukemogenesis through AID-independent
mechanisms.
Results
In vivo Aid expression in preleukemic precursor B cells. AID is
responsible for the induction of secondary diversification of
immunoglobulin (Ig) genes in secondary lymphoid organs in
response to antigen. AID initiates SHM and also Ig class
switching, but it can also promote chromosomal translocations
and mutations with an etiological role in B-cell lymphomagen-
esis16–19,26. We have recently shown that exposure to natural
infectious pathogen triggered clonal evolution toward B-ALL4,13.
Based on these findings, we asked whether AID is required for
clonal evolution of pre-malignant precursor B cells in the etiology
of native (non-transplant) infection-associated B-ALL. Thus, we
first investigated if high levels of AID were present in in vivo
preleukemic precursor B cells purified from mice carrying a
genetic susceptibility to B-ALL (either Pax5 heterozygosity or the
presence of the ETV6-RUNX1 fusion gene), which are exposed to
natural infections (Supplementary Fig. 1a). Both mouse models
only develop B-ALL under natural infection exposure4,13. In
agreement with previous results21, AID was not detectable in
preleukemic precursor B cells isolated from the bone marrow
(BM) of mice kept under SPF (germ-free) conditions (Supple-
mentary Fig. 1a). Similarly, AID expression levels were not
upregulated in preleukemic precursor B cells isolated from BM of
mice kept in conventional (natural infection) housing (Supple-
mentary Fig. 1a). In a previous study22, withdrawal of IL7 and
repeated ex vivo exposure of Fraction D pre-B cells to inflam-
matory stress (LPS) resulted in high levels of AID mRNA and
protein expression. However, the exposure to natural infection
does not significantly increase AID expression in preleukemic
precursor B cells (Supplementary Fig. 1a), although in vitro
exposure of preleukemic Pax5-het, and Sca1-ETV6-RUNX1 pre-
cursor pro-B cells to different immune activation stimuli resulted
in high levels of AID mRNA (Supplementary Fig. 1b).
Natural infections drive B-ALL in the absence of AID. Given
the clonal nature of leukemia, we cannot exclude that Aid would
be overexpressed at a single preleukemic precursor B cell in our
model for in vivo exposure to natural infection. To test a cau-
sative role of AID in native infection-driven B-ALL development,
we employed Aicda/Aid-KO mice to study loss of AID function in
the clonal evolution of pre-malignant B cells in the etiology of
infection-associated B-ALL. PAX5 is a gene commonly mutated
in B-ALL6. Pax5-het mice are prone to develop B-ALL only after
natural infection exposure4. Likewise, Pax5-het mice used as
sentinels of an ongoing similar infectious stimuli within the
facilities are permanently kept either in a specific pathogen-free
(SPF) animal house during their lifespan or transferred to natural
infection exposure as described4, where the microbiologic status
is defined and controlled (Supplementary Tables 1, 2). Pax5-het
mice housed under SPF environment have not spontaneously
developed B-ALL unless were exposed to natural infection
environment, corroborating previous results4. Thus, Pax5-het/
Aid-het and Pax5-het/Aid-KO animals were exposed to identical
natural infection environment (Fig. 1a; Supplementary Tables 1,
2), and B-ALL development was monitored and analyzed in these
strains as previously described4. Surprisingly, under this scenario,
B-ALL development was observed in 30.4% (7 out of 23) of Pax5-
het/Aid-het and in 30% (9 out of 30) of Pax5-het/Aid-KO animals,
respectively (Fig. 1b), closely resembling the penetrance of B-ALL
development in both the Pax5-het group4 and the carriers with
the heterozygous PAX5 c.547G>A mutation7. The advent of
leukemia in either Pax5-het/Aid-het or Pax5-het/Aid-KO back-
ground under natural infection exposure occurred at between 7
and 20 months of age (Fig. 1b), similar to the Pax5-het group4.
These Aid-het or Aid-KO B-ALLs became manifest due to blast
infiltration and presence of tumor cells in the peripheral blood
(PB) (Fig. 1c; Supplementary Fig. 2). FACS analysis revealed
the expected CD19+/−B220+IgM−cKit+/−CD25+/− cell surface
phenotype for B-cell blasts that infiltrated both hematopoietic
tissues like BM, PB, spleen, and lymph nodes (Fig. 1c; Supple-
mentary Figs. 2–4) and nonlymphoid tissues, such as the liver and
lung (Supplementary Figs. 3, 4). Likewise, both groups of B-ALL,
Pax5-het/Aid-het and Pax5-het/Aid-KO, also presented a similar
percentage of blast cells infiltrating BM, spleen, and PB (Sup-
plementary Fig. 5). Similar to the Pax5-het group, all Pax5-het/
Aid-het or Pax5-het/Aid-KO B-ALLs displayed clonal immu-
noglobulin VH-DJH and D–JH gene rearrangements consistent
with a pro-B or pre-B-cell origin (Supplementary Fig. 6), and the
DJ/VDJ junctions did not show specific features regarding the
junctions or choice of V, D, and J segments (Supplementary
Fig. 7). Likewise, we next identified differentially expressed genes
(FDR= 0.01) in leukemic BM from both Pax5-het/Aid-het
(Supplementary Fig. 8 and Supplementary Data 1) and Pax5-het/
Aid-KO (Supplementary Fig. 9 and Supplementary Data 2) mice
compared with BM precursor B cells from wild-type mice,
showing that AID-deficient B-ALL exhibited a gene expression
pattern that is similar to AID-het B-ALL (Supplementary Fig. 10).
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To explore the relevance of our findings in human leukemia, we
compared the role of AID activity on mRNA expression derived
from tumor cells from patients with B-ALL expressing or
not AID27,28. Although AID-deficient B-ALL exhibited a gene
expression pattern similar to these human B-ALL28 (FDR=
0.005; FDR= 0.002) (Fig. 1d), the gene expression profiles
between Pax5-het/Aid-KO B-ALL and Pax5-het/Aid-het B-ALL
did not show any differences between them when we compared
with gene expression profile derived from tumor cells from
patients with B-ALL expressing or not AID27,28 (FDR= 0.290;
FDR= 0.505) (Fig. 1e), indicating that the AID is not sig-
nificantly contributing to the leukemic gene expression profile of
infection-driven B-ALL.
In order to further identify somatically acquired 2nd hits
leading to leukemia development in both Pax5-het/Aid-het and
Pax5-het/Aid-KO B-ALLs, we performed whole-exome sequen-
cing of five Pax5-het/Aid-het tumors, eight Pax5-het/Aid-KO
tumors, and paired samples of germline tail DNA as a reference.
We could identify between 8 and 58 somatic single-nucleotide
variations (SNVs) in the tumor samples of Pax5-het/Aid-het mice
and between 11 and 27 somatic SNVs in the tumor samples of
Pax5-het/Aid-KO mice. According to the cancer gene consensus
database29, the somatic cancer SNVs ended in 0–4 SNV per
mouse (Fig. 2a). Furthermore, we analyzed these present SNVs
and could show that Pax5-het/Aid-het and Pax5-het/Aid-KO
mouse tumors carry mutations in the same genes as well as
mutations that are specific for the genotypes (Fig. 2b; Table 1).
Similar genes (Pax5, Trp53, and Ptpn11) were mutated in
both Pax5-het/Aid-het and Pax5-het/Aid-KO leukemic cells.
Notably, the drivers of mouse infection-associated B-ALL are
not preferentially targeted by AID (Supplementary Table 3).
Consistently, tumor Pax5-het/Aid-het and Pax5-het/Aid-KO pro-
B cells grow independent of IL7 and can initiate leukemia in
secondary transplant recipients (Supplementary Fig. 11).
Furthermore, we analyzed the tumor mutational pattern
and the mutation spectrum indicated a general prevalence of
transitions between pyrimidines in the sample set (Fig. 3a).
COSMIC signatures 1, 3, and 12 had the highest overall relative
contribution30, but no signature was specific for the tumor
subsets (Fig. 3b). A de novo signature analysis revealed no
significant differences between tumor and control groups (Fig. 3c,
d); both signature candidates reflected the overall mutation
spectrum. For this analysis, nonnegative matrix factorization
(NMF) was applied as dimension reduction technique. The
similarity between original and reconstructed mutation spectrum
was high (cosine similarity SC: SC (original, COSMIC)= 0.94 for
a
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Fig. 1 Contribution of AID to the genesis of native infection-driven B-ALL. a Experimental design. Mice permanently kept either in a SPF animal house
during their lifespan or transferred to natural infection exposure between 4 and 5 weeks after birth. b Comparison between B-ALL-specific survival of Aid-
het mice (light blue, n= 15), Aid-KO mice (deep blue, n= 15), Pax5-het/Aid-het mice (violet, n= 23), Pax5-het/Aid-KO mice (green, n= 30), Pax5-het
animals (red, n= 41), and WT control mice (black, n= 20). Pax5-het/Aid-het or Pax5-het/Aid-KO mice showed a significantly shortened lifespan (log-rank
p-value= 0.0061) (upper panel) that was similar to the Pax5-het group (lower panel) (log-rank p-value= 0.7412). c Flow cytometric analysis of
hematopoietic subsets in diseased Pax5-het/Aid-het and Pax5-het/Aid-KOmice. Comparison between leukemic BM showing conglomeration of blast B cells
in Pax5-het/Aid-hetmice (n= 7; age, 9–20 months) and Pax5-het/Aid-KO mice (n= 9; age, 7–17 months) and normal BM showing normal B cells in control
littermate age-matched WT mice (n= 4; age, 8–16 months). d GSEA of leukemic Pax5-het/Aid-KO B cells. GSEA identified significant enrichment in human
BCR-ABL B-ALL genesets28 in Pax5-het/Aid-KO tumor-bearing BMs compared with sorted purified pro/pre-B cells from BM of WT mice (GSEA FDR=
0.005, and FDR= 0.002). e GSEA results showing no significant (FDR > 0.25) enrichment of human BCR/ABL B-ALL genesets25 between leukemic Pax5-
het/Aid-het and leukemic Pax5-het/Aid-KO phenotypes.
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the COSMIC decomposition, and SC (original, de novo)= 0.96
for the de novo analysis). These observations surprisingly
revealed that clonal evolution of pre-malignant B-cell precursors
toward B-ALL as a result of in vivo natural infection exposure
took place through the acquisition of secondary genetic events
unrelated to AID activity in mouse models mimicking human
genetic predisposition to B-ALL.
Premature Aid expression in B cells does not trigger B-ALL.
Subsequently, we investigated whether aberrant in vivo AID
function generates driver mutations in BM precursor B cells with
physiological RAG V(D)J recombinase. In order to achieve this,
we made use of a conditional mouse model for Aid expression
where a cassette harboring the Aicda and EGFP cDNAs separated
by an internal ribosomal entry site (IRES) sequence was placed
inside the Rosa26 endogenous locus. The Aid-EGFP cassette is
preceded by a floxed transcriptional stop sequence that prevents
Aicda expression (Rosa26+/Aid mice31; Supplementary Fig. 12).
Rosa26+/Aid mice were bred to the Mb-1-Cre deleter strain32 to
promote AID expression from early pro-B-cell stages of B-cell
differentiation. We found that aberrant AID expression in BM
precursor B cells did not affect mouse survival or triggered B-cell
neoplasia development (Fig. 4a), although we detected GFP
expression starting at the pre-pro-B-cell stage and in virtually
100% of pro-B cells and at all subsequent differentiation stages
(Fig. 4b). We next assessed AID activity in immunoglobulin (Ig)
genes in splenic (Fig. 4c) and bone marrow B cells (Fig. 4d). We
observed that pro-B cells seem to be the most permissive stage for
AID activity since the SHM does not increase significantly later in
B-cell differentiation (Fig. 4d).
In agreement with previous studies33–36, we observed that
premature expression of AID in precursor B cells did not induce
B-cell malignancies. However, it was previously shown that the
combination of AID transgenic expression driven by kappa light-
chain regulatory sequences (IgκAID mice) with p53 deficiency
increased the proportion of B-cell lymphomas compared with
p53−/− mice37. These results were interpreted as an indication that
AID-induced genetic lesions are under tight control of Tp53 tumor
suppressor that eliminates B cells that sustained extensive DNA
damage. For this reason, we additionally bred Rosa26+/Aid mice to
tumor p53 suppressor-deficient background (Tp53−/−). However,
Aicda overexpression did not affect the development of B-cell
lymphomas (Fig. 4a). At present, we cannot tell whether this
discrepancy is due to the higher AID expression levels achieved by
the IgκAID transgene compared with our Rosa26+/Aid Mb1-Creki/+
mice, or to the fact that IgκAID is expressed later during B-cell
differentiation and induced upon B-cell activation, or related to the
random genomic insertion occurring when classical transgenic
procedures are used33. Regardless of the reason, our data show that
the aberrant AID expression in Rosa26+/Aid Mb1-Creki/+ mice
that promotes intense off-target mutagenic activity initiated at the
earliest stages of B-cell development is not sufficient to drive
precursor B-cell transformation. Notably, this finding was also
substantiated in humans, since AID off-targets26 are not signifi-
cantly enriched in human B-ALL drivers38 (Supplementary
Fig. 13 and Supplementary Table 4).
Discussion
The current view in the field of B-cell leukemogenesis states that
AID expression is induced in preleukemic B-cell precursor cells in
response to infection and promotes in this case secondary genetic
changes that may lead to subsequent leukemia development22–25.
The main experimental approach used to decipher the process of
infection-driven leukemogenesis has relied on ex vivo functional
assays involving transplantation, and it has been focused in a
specific stage of B-cell development, the late pre-B cells at the
time of κ-light-chain rearrangement22. Repeated in vitro forced
stimulation with IL7-withdrawal to drive κ-light-chain gene
rearrangement and LPS inflammatory stimuli of these late pre-B
cells at the time of κ-light-chain expression resulted in a > 100-
fold increase of AID protein levels22. Downregulation of IL7R
signaling and concomitant activation of RAG1 were both
required to promote malignant transformation22. In agreement
with this observation, the combination of deregulated AID
expression close to the loss of 53BP1 in late pre-B cells at the time
of κ-light-chain expression gave rise to B-cell transformation39.
However, it is not known to what extent this mechanism is shared
by the pro-B or pre-B cells, stage of B-cell development which
drives common B-cell precursor ALL, in the context of native
(non-transplant) infection-driven B-ALL development4,13,24. In
agreement with the previous observation39, we found that in vitro
exposure of preleukemic pro-B cells to different immune activa-
tion stimuli resulted in a significant increase of AID mRNA
(Supplementary Fig. 1b). However, natural infection exposure
does not increase Aid expression in preleukemic precursor B cells
in vivo (Supplementary Fig. 1a), although these results cannot
exclude that Aid might be overexpressed at single preleukemic
precursor B cell as a result of in vivo exposure to natural infec-
tion. In this paper, we addressed this question using two novel
genetic in vivo models: an experimental mouse model that
develops B-ALL only in response to natural infection (the “pax5-
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Fig. 2 Mouse tumor exome sequencing in Pax5-het/Aid-het mice and Pax5-het/Aid-KO native B-ALL. a Whole-exome sequencing analysis of tumor and
control samples. Tumor-specific somatic mutations were determined by mutect and varscan analysis. The number of somatic cancer genes were calculated
by using the cancer gene consensus list. b Genomic comparison between mutations driving native B-ALL as a result of natural infection exposure of Pax5-
het/Aid-het (violet) and Pax5-het/Aid-KO mice (light blue), respectively, showed that similar second hits were affected by recurrent mutations.
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to disease penetrance, clinical and genomic characteristics), and a
complementary mouse model for conditional Aid expression in
B-cell precursors. Using these two models, we clearly show that
ex vivo approaches are not representative for the in vivo situation
in this case. We demonstrate that Aid expression levels are not
upregulated in pre-malignant pro-B or pre-B-cell precursors in
mice prone to develop B-ALL under natural infection exposure.
Similarly, enforced AID mutagenic activity in these pro-B and
pre-B cells did not promote B-ALL development, and known
drivers of human B-ALL are not preferentially targeted by AID.
Likewise, patients with B-ALL have relatively few SNVs, and
rarely have chromosomal translocations into the IGH switch
region. In this regard, it is worth noting that AID activity is
closely associated to transcription and usually occurs near tran-
scription start sites and linked with multiple promoter and
enhancer regions, most likely to facilitate AID accessibility19,40,41.
Therefore, off-target AID activity is likely to differ between early
B-cell precursors—driving leukemogenesis—and germinal center
B cells—giving rise to mature B-cell lymphomas—according to
the transcriptional configuration associated with each differ-
entiation stage. Likewise, the presence or absence of AID does not
impact on the latency or incidence of infection-mediated B-ALL
development. This Aid-independently emerged B-ALL closely
resembles childhood B-ALL in both clinical characteristics
and leukemia-associated genetic alterations. Our study therefore
provides evidence for a substantially revised model of leukemo-
genesis triggered by infection.
As opposed to AID-driven B-cell lymphomagenesis, where the
penetrance of the disease is very high20, the discovery that
infection-mediated native B-ALL takes place without AID con-
tribution is consistent with the fact that only a minority of healthy
newborns harboring a preleukemic clone evolve to overt B-ALL42.
This fact makes it more plausible that this infection-driven leu-
kemogenesis process might be prevented4,13,24,43. In addition,
these findings have also potential implications for the clinical use
of PI3Kδ or Bruton’s tyrosine kinase inhibitors in the treatment
of B-cell leukemias44,45. The introduction of these inhibitors into
the clinic could change how B-cell leukemias are treated44.
However, the increase of AID levels induced by these inhibitors
only after drugs treatment in vitro, and in tumor cell lines
has been considered one of their major limitations as it may affect
genomic stability in precursor B cells46,47. Furthermore, a sig-
nificant AID activity on DNA of treated patients was only
demonstrated for PI3Kδ. However, no B-ALL development has
been reported so far by current use of targeted therapy with the
PI3Kδ inhibitor in patients with activated PI3Kδ syndrome
(APDS)48. In this regard, and in contrast with recent data derived
from studies based on in vitro and in tumor cell lines46, recent
observations have demonstrated that ibrutinib therapy results in a
profound reduction in both AID expression and proliferative
leukemic fractions in treated patients49. Overall, this work high-
lights the unique potential of the application of this in vivo native
assay to identify the importance of drivers of B-cell precursor
ALL in the context of infectious exposure or any other environ-
mental factors.
Methods
Mouse model for natural infection-driven leukemia. Pax5-het mice were crossed
with Aid-KO mice14 to generate Pax5-het/Aid-het and Pax5-het/Aid-KO. These
Pax5-het/Aid-het and Pax5-het/Aid-KO mice were bred and maintained in the SPF
area of the animal house until the moment when they were relocated to an
environment where natural infectious agents were present, as previously descri-
bed4. All mouse experiments were performed following the applicable Spanish and
European legal regulations, and had been previously authorized by the pertinent
institutional committees of both University of Salamanca and Spanish Research
Council (CSIC). Aid-het, Aid-KO, Pax5-het/Aid-het, and Pax5-het/Aid-KO mice of
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equal representation of both males and females. For the experiments, Aid-het, Aid-
KO, Pax5-het/Aid-het, and Pax5-het/Aid-KO of the same litter were used. When
the animals showed evidences of illness, they were humanely killed, and the main
organs were extracted by standard dissection. All major organs were macro-
scopically inspected under the stereo microscope, and then representative samples
of tissue were cut from the freshly dissected organs, and were immediately fixed.
Oncogenic priming of B cells by premature expression of Aid. Rosa26AID
knock-in mice were generated by our group and described previously31. Rosa26AID
mice were crossed with Mb-1cre32,, P53−/−37, and Ink4/Arf−/−50,, respectively. Aid-
KO mice14 were used as negative control for SHM assays. Both males and females’
littermates aged from 6 to 12 weeks were used for experiments. All animals were
housed in the Centro Nacional de Investigaciones Cardiovasculares animal facility
under SPF conditions. All animal procedures conformed to EU Directive 2010/
63EU and Recommendation 2007/526/EC regarding the protection of animals used
for experimental and other scientific purposes, enforced in Spanish law under RD
53/2013. The procedures have been reviewed by the Institutional Animal Care and
Use Committee (IACUC) of Centro Nacional de Investigaciones Cardiovasculares,
and approved by Consejeria de Medio Ambiente, Administración Local y Orde-
nación del Territorio of Comunidad de Madrid.
Mutation analysis by next-generation sequencing (NGS). Analysis of mutations
at Sμ by NGS was performed as described in Pérez-Durán P et al.51. Briefly, naive B
cells were purified by immunomagnetic depletion with anti-CD43 beads (Miltenyi)
and cultured with 25 μg/ml LPS (Sigma) plus 10 ng/ml IL4 (PeproTech) for 3 days
to obtain activated B cells. Immature B-cell populations were purified by FACs-
sorting as follows: B220+ CD19−, pre-pro-B; B220+ CD19+ IgM-CD25− pro-B;
B220+ CD19+ IgM-CD25+ pre-B; B220+CD19+ IgM+ IgD−, immature.
Genomic DNA from purified B-cell populations was extracted, and PCR amplified
with Pfu Ultra high-fidelity DNA polymerase (Stratagene). PCR reactions were
fragmented with Covaris, and adapter-ligated libraries were generated, processed,
and sequenced on a HiSeq2500 according to the manufacturer’s instructions
(Illumina).
Flow cytometry, cell sorting, and cell viability assays. The total mouse BM cells
were obtained by washing the long bones with PBS with 1% FCS, using a 27-G
needle. Cells were as well collected from peripheral blood, and also from the
thymus and spleen after disrupting these organs by passing them through a 70-μm
cell strainer. Erythrocytes were osmotically lysed using RCLB buffer, and nucleated
cells were then washed with PBS–1% FCS. Cells were stained with the appropriate
antibodies against the indicated cellular markers for 20 min at 4 °C, washed
once with PBS–1% FCS, and finally they were resuspended in PBS–1% FCS with
10 μg/mL propidium iodide (PI) to exclude dead cells during data acquisition; this
was performed in an AccuriC6 Flow Cytometer, and data files were analyzed using
Flowjo software. For this analysis, gates were set by employing the commonly used
forward and perpendicular light-scattering properties of mouse hematopoietic cells,
and the specific fluorescence of the staining dyes used [FITC, PE, PI, and APC
excited at 488 nm (0.4W) and 633 nm (30 mW), respectively]; an example of
such a gating strategy is shown in Supplementary Fig. 14. The nonspecific binding
of staining antibodies to the Fc receptors of immune cells was prevented by
incubating the samples with anti-CD16/CD32 Fc-block solution (clone 2.4G2,
cat. #553142, BD Biosciences) for 20 min at 4 °C, previously to the addition of
the staining antibodies. For each sample tube, a minimum of 50,000 living (i.e.,





















































































































































































































































































































Fig. 3 Mutational patterns in Pax5-het/Aid-het and Pax5-het/Aid-KO B-ALL. a Mutation spectrum of total identified SNPs after filtering (median: 524
SNPs per sample). b Spectrum decomposition with COSMIC signatures as basis. COSMIC signatures 1, 3, and 12 showed the highest overall relative
contribution, while no signature indicated tumor-specific enrichment. c De novo signature results for a nonnegative matrix factorization decomposition with
two signatures. Enrichment of mutation contexts mirrored the original mutation spectrum for both signatures. d De novo signature contribution for
signatures shown in (c), with clustering (complete-linkage). No tumor-specific cluster was identified.
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The antibodies used for flow cytometry were all from BD Biosciences: anti-B220
(clone RA3-6B2, cat. #103212, used in 1:100 dilution), CD4 (clone RM4-5, cat.
#100516, used in 1:250 dilution), CD8a (clone 53-6.7, cat. #100708, used in 1:250
dilution), CD11b/Mac1 (clone M1/70, cat. #553310, used in 1:200 dilution), CD19
(clone 1D3, cat. #152404, used in 1:100 dilution), CD117/c-Kit (clone 2B8, cat.
105807, used in 1:200 dilution), Ly-6G/Gr1 (clone RB6-8C5; cat. #108412, used in
1:100 dilution), IgM (clone R6-60.2, cat. #406509, used in 1:100 dilution) and
CD25 (clone PC61, cat. #553866, used in 1:100 dilution). The gating strategy is
exemplified in Supplementary Fig. 14.
Real-time PCR quantification (Q-PCR) of Aicda. Expression of Aid was analyzed
in sorted BM precursor B (B220low IgM−) cells of wild-type, Pax5-het, and Sca1-
ETV6-RUNX1 mice in two environmental conditions (mice housed in conventional
facility and mice housed in an SPF facility) by Q-PCR as follows. cDNA for use in
quantitative PCR studies was synthesized using reverse transcriptase (Access RT-
PCR System; Promega, Madison, WI, USA). Real-time PCR reactions were per-
formed in an Eppendorf MasterCycler Realplex machine. Assays used for quan-
titative PCR are commercially available from IDT (Integrated DNA Technologies):
AID (Assay ID: Mm.PT.58.42247522) and GAPDH (Assay ID: Mm.PT.39a.1).
In addition, the probes were designed so that genomic DNA would not be detected
during the PCR. Measurement of GAPDH gene product expression was used as an
endogenous control. The total spleen from immunized mice was used as a positive
control of Aicda expression, and sorted BM pro/pre cells from Aid-KO mice were
used as a negative control. All samples were run in triplicate. The comparative CT
Method (ΔΔCt) was used to calculate relative expression of the transcript of
interest and a positive control. The change in threshold cycle (ΔCt) of each sample
was calculated as the Ct value of the tested gene (target) minus the Ct value of
GAPDH (endogenous control). The ΔΔCt of each sample was obtained by
subtracting the ΔCt value of the reference from the ΔCt value of the sample. The
ΔCt reference value used was the ΔCt obtained from the total spleen of wild-type
immunized mice. The fold change in each group, calculated as 2–ΔΔCt sample, was
compared.
In vitro Aid expression in preleukemic pro-B cells. Pro-B cells were obtained
from the BM of 2–3 weeks old WT, Sca1-ETV6-RUNX1 and Pax5-het mice,
respectively. B cells were isolated from the BM via positive MACS separation for
B220. Cells were cultivated in special pro-B-cell medium (IMDM medium+ L-
glutamine+HEPES, 2% FCS, 1 mM penicillin–streptomycin, 0.03% Primaton,
50 µM beta-mercaptoethanol, 2 µg/ml cyproxin) supplemented with 5 ng/ml
murine recombinant IL7 on ST2-feeder cells. Subsequently, pro-B cells were sti-
mulated with TLR stimuli (LPS 40 µg/ml, PIC 25 µg/ml, R848 3 µg/ml, CpG (ODN
1668) 6 µg/ml; all from the company invivo Gen) and RT-PCR was performed for
analysis of Aid expression (forward primer: GGGTCGTGAATGATGCTCTT,
reverse primer: TGGCTTGTGATTGCTCAGAC).
Histology. Mice were euthanized by cervical dislocation. The tissue samples
obtained after dissection were fixed in formaline and then included in paraffin
following standard procedures. Hematoxylin–eosin stainings of representative
sections were used for histopathology evaluation, performed under the supervision
of Dr. Oscar Blanco, professional pathologist of human samples at the Salamanca
University Hospital. For Tp53−/− background tumoral occurrence, lymphoid tis-
sues were evaluated by histology, immunohistochemistry, and flow cytometry.
Animals presenting tumors were classified into four categories according to the
presence of solid tumors only or B/T-lymphomas independently of co-occurrence
































































































Total WRC WRCY AGCT
10.1 96.6 99.0 99.5 99.2 99.4















Fig. 4 Early expression of AID in precursor B cells has no effect in lymphomagenesis. a Kaplan–Meier survival graph for R26+/AID Mb-1+/cre and R26+/+
Mb-1+/cre control mice in WT and Tp53−/− backgrounds. The number of mice in each group is indicated in brackets. Median survival for R26+/AID Mb-1+/cre
Tp53−/−, 22 weeks. Histopathology analysis of tumoral mice in Tp53−/− background. TL T lymphoma, BL B lymphoma. b GFP is fully expressed from the pro-
B-cell stage on. GFP reporter expression in developing B cells of R26+/AID Mb-1+/cre mice (black line) and Rosa26+/+ Mb-1+/cre control mice (gray shaded) in
the bone marrow and naive B cells in the spleen. Populations were defined as B220+CD19−, pre-pro-B; B220+CD19+ IgM-CD25− pro-B; B220+CD19+
IgM-CD25+ pre-B; B220+CD19+ IgM+ IgD−, immature; B220+CD19+ IgD+ , recirculating; B220+ , spleen naive. c SHM by R26-AID. SHM in Sμ region
was analyzed by NGS in naive B cells purified from R26+/AID Mb-1+/cre and Rosa26+/+ Mb-1+/cre control mice. Aicda−/− B cells were used as control for
technical background. Total mutation frequency and specific mutation frequency in C or G within AID hotspots (WRC, WRCY, and AGCT) is indicated. Two
mice per genotype and one Aicda−/− were analyzed. d SHM as measure of R26-AID activity in immature B-cell populations. Sorted B-cell populations from
the bone marrow, purified naive, and LPS/IL4 activated B cells were used to analyze SHM in Sμ region as in c. Mutation frequency within WRCY AID hotspots
is indicated. A pool of two mice per BM/naive populations and two independent mice for activated B cells were analyzed.
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V(D)J recombination. The recombination of the immunoglobulin genes was
analyzed by a PCR protocol based on the amplification of the possible products of
V(D)J rearrangements based on the use of a primer immediately downstream of
the JH4 segment in several combinations with 5′ primers specific for the different
families of VH segments. The primers are described in Table 2. PCR conditions
were denaturation at 95 °C for 5 min, followed by 31–37 cycles of [(95 °C, 60 s)+
(65 °C, 60 s)+ (72 °C, 105 s)], followed by a final elongation step of 70 °C, 10 min.
Then, PCR products were run on an agarose gel, and individual bands corre-
sponding to specific rearrangements were isolated, cloned into the pGEM-T-easy
vector (Promega), and sequenced; at least ten independent clones were sequenced
for each individual band analyzed in order to determine the potential clonality of
the rearrangement.
We have sequenced a selection of the PCR clonal bands, and have analyzed the
V(D)J junction sequences with both IMGT/V-QUEST (http://www.imgt.org/)52
and IgBLAST (www.ncbi.nlm.nih.gov/igblast)53. The information related to the
primers used, band sizes, and the corresponding sequences are indicated in
Supplementary Table 5.
Microarray data analysis. The total RNA was first isolated using TRIzol (Life
Technologies), and then it was subjected to purification with the RNeasy Mini Kit
(Qiagen) using also the On-Column DNase treatment option. Quality and quan-
tification of RNA samples were determined by electrophoresis.
Determination of the expression of the different genes in the RNA samples was
performed using Affymetrix Mouse Gene 1.0 ST arrays. All bioinformatic analyses
of the array data were performed using R54 and Bioconductor55. First, we applied
background correction, intra- and inter-microarray normalization, and expression
signal calculation using the microarray analysis algorithm56–58, in order to
determine the absolute expression signal for each gene in each array. Then, we used
the significance analysis of microarray (SAM)59 method to identify the gene probe
sets with differential expression between experimental and control samples, SAM
uses a permutation algorithm to allow to statistically infer the significance of the
differential expression, and it provides P-values adjusted to correct for the multiple
testing problem, by using FDR60. An FDR cutoff of <0.05 was used as a threshold
to determine differential expression.
Enrichment analysis. In order to identify potential signatures of gene expression
associated with different biological processes, gene set enrichment analysis (GSEA)
was performed using the MSigDB databases from the Broad Institute28,61,62. Gene
expression signatures that have been previously found to be specifically deregulated
in human B-ALLs28,62,63 were also analyzed to determine their potential overlap
with the ones that were found up- or downregulated by the GSEA analysis of our
tumor samples.
Mouse exome library preparation and NGS. DNA was purified from samples
using the AllPrep DNA/RNA Mini Kit (Qiagen) according to the manufacturer’s
instructions. The exome library was prepared using the Agilent SureSelectXT
Mouse All Exon Kit with some modifications. Exome capture was performed by
hybridization to an RNA library according to the manufacturer’s protocol. Then,
the captured library was purified and enriched by binding to MyOne Streptavidin
T1 Dynabeads (Life Technologies) and posterior off-bead PCR amplification in the
linear range. Sequencing (2 × 100 bp) was carried out in a HiSeq2500 (Illumina)
using the TruSeq SBS Kit v3 with a 6-bp index read.
Data analysis. Fastq files were generated with Illumina BcltoFastq 1.8.4. The
alignment of the sequence data to the GRCm38.71 mouse reference genome was
performed with BWA version 0.7.4. SAMtools was used for conversion steps and
removal of duplicate reads. GATK 2.4.9 was used for local realignment around
indels, SNP-calling, annotation, and recalibration. For recalibration, mouse
dbSNP138 and dbSNP for the used mouse strains were used as training data sets.
The variation calls obtained in this way were then annotated using the v70 Ensembl
database with variant effect predictor (VEP), incorporating loss-of-function pre-
diction scores for PolyPhen2 and SIFT. Afterward, the information was imported
into an in-house MySQL database for further annotation, reconciliation, and data
analysis by complex database queries if required.
Somatic calls were the output from MuTect64 and VarScan65. For VarScan2
results, false-positive filtering was used as indicated by the author. In order to
increase the reliability of the results, only calls having at least a 9% difference in
allele frequency between tumor and normal samples were considered for further
analysis. Cancer-related genes were singled-out by using the information from the
Catalogue of Somatic Mutations in Cancer (COSMIC)66 after having translated the
cancer gene consensus from COSMIC by making use of Ensembl’s BioMart67.
Sequencing. Classical Sanger sequencing was used for the validation of mutations,
using a 3130 Genetic Analyzer (Applied Biosystems). The sequencing primers used
were: mJak3 forward: CGGGATGTGGGGCTTTAACT, reverse: GCAGACACGG
GGTATAGTGG; mPax5 forward: CTCGTACATGCACGGAGACA, reverse: GGA
CCCTTCAGTACACCAGC.
Pro-B-cell culture. Pro-B cells were purified from BM using magnetic-activated
cell sorting, selecting with anti-B220 beads (Milteny Biotec). Pro-B cells were
maintained and expanded by culturing them in Iscove’s Modified Dulbecco’s
Medium (IMDM) supplemented with 50 μM β-mercaptoethanol, 1 mM L-Gln, 2%
heat-inactivated FCS, 1 mM penicillin–streptomycin (BioWhittaker), 0.03% (w/v)
primatone RL (Sigma), and 5 ng/ml mrIL7 (R&D Systems), in the presence of
Mitomycin C-treated ST2-feeder cells. Tumor pro-B cells that could grow inde-
pendently of IL7 were grown in the same medium without this cytokine.
Transplantation. IL7-independent Pax5-het/Aid-het and Pax5-het/Aid-KO pro-B
cells were intravenously injected into 12-week-old male syngenic mice (C57BL/6×
CBA) that had previously been sublethally irradiated (4 Gy). Leukemia develop-
ment in the injected mice was followed by regular analysis of peripheral blood,
until the moment when leukemic blasts were detected in the blood; at this point,
animals were killed and analyzed to characterize B-ALL development.
Mutational pattern analysis in B-ALL. Samples were subjected to a standardized
alignment with [BWA-mem], and a preprocessing step consisting of [GATK rea-
lignment, recalibration, trimming tool single-nucleotide variants were identified for
Pax5-het/Aid-het and Pax5-het/Aid-KO B-ALL and control samples with Platypus
version 0.8.1 and default parameters68. Control variants were pooled and removed
from each tumor sample’s variant list, and vice versa. Furthermore, all variants
with a quality score < 100 were discarded. Mutational signature analyses were
subsequently conducted with the R/Bioconductor package MutationalPatterns,
version 1.6.169.
Statistical analysis. The comparisons for the average values between two sample
groups were made by two-tailed Student’s t test or Wilcoxon’s rank-sum test with
GraphPad Prism software or R software. Mice survival was analyzed using
Kaplan–Meier representation of the different cohorts, and statistics for differential
survival were performed using the log-rank (Mantel–Cox) test. For in vivo trans-
plantation experiments, the minimal number of mice in each group was calculated
through use of the “cpower” function in the R/Hmisc package. The level of sig-
nificance was set at P < 0.05.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Authors can confirm that all relevant data are included in the paper and/or its
supplementary information files. All data reported in this article are deposited in the
NCBI’s Gene Expression Omnibus (GEO)70, and are available under the GEO Series
accession number GSE122105. The source data underlying Supplementary Fig. 6 is
provided as a Source Data file.
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